Regeneron (REGN) Tops Q2 EPS by 104c, Sales Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Grand Canyon Education places CFO on leave amid stock trade probe
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Funds sell $44bn in semiconductors on AI concerns
Regeneron Pharma (REGN) PT Raised to $472 at Goldman Sachs
August 4, 2017 7:00 AM EDTGoldman Sachs raised its price target on Regeneron Pharma (NASDAQ: REGN) to $472.00 (from $469.00) while maintaining a Neutral rating.
... MoreRegeneron Pharma (REGN) PT Raised to $455 at JPMorgan
August 4, 2017 6:58 AM EDTJPMorgan raised its price target on Regeneron Pharma (NASDAQ: REGN) to $455.00 (from $427.00) while maintaining a Neutral rating.
... MoreRegeneron Pharma (REGN) PT Raised to $580 at Leerink Partners
August 4, 2017 6:55 AM EDTLeerink Partners raised its price target on Regeneron Pharma (NASDAQ: REGN) to $580.00 (from $573.00) while maintaining a Outperform rating.
... MoreRegeneron Pharma (REGN) PT Raised to $575 at Citi
August 4, 2017 6:53 AM EDTCiti raised its price target on Regeneron Pharma (NASDAQ: REGN) to $575.00 (from $555.00) while maintaining a Buy rating.
... More